This 90-minute livestreamed activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
In this Creative Educational Concepts (CEC) livestream symposium, expert faculty will discuss strategies for differentiating patient- and disease-specific variables that inform CLL treatment selection, developing plans for managing new AEs, and addressing patient-related treatment barriers to improve adherence to CLL therapy.
The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy.
In this Creative Educational Concepts Enduring Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.
This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events.
Join our expert faculty for this 60-minute program that will help you understand the complexity of TNBC and the far-reaching racial disparities intrinsic to the disease.
This is a live webcast addressing emerging therapeutic options for gastric, GEJ, and EAC cancers. This activity will address PD-L1 expression and its impact on treatment selection and sequencing, as well as the role of interprofessional care in managing irAEs.